Fiche du document
1 juillet 2019
- doi: 10.1084/jem.20182359
- issn: 0022-1007
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1084/jem.20182359
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31123083
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1540-9538
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0B420592FE763
info:eu-repo/semantics/openAccess , CC BY-NC-SA 4.0 , https://creativecommons.org/licenses/by-nc-sa/4.0/
Sujets proches
Mouse House mice Mus musculus House mouseCiter ce document
C. Fenwick et al., « Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. », Serveur académique Lausannois, ID : 10.1084/jem.20182359
Métriques
Partage / Export
Résumé
Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1-PDL-1 interaction. Here, we have identified novel antagonistic anti-PD-1 Abs not blocking the PD-1-PDL-1 interaction. The nonblocking Abs recognize epitopes on PD-1 located on the opposing face of the PDL-1 interaction and overlap with a newly identified evolutionarily conserved patch. These nonblocking Abs act predominantly through the CD28 coreceptor. Importantly, a combination of blocking and nonblocking Abs synergize in the functional recovery of antigen-specific exhausted CD8 T cells. Interestingly, nonblocking anti-PD-1 Abs have equivalent antitumor activity compared with blocker Abs in two mouse tumor models, and combination therapy using both classes of Abs enhanced tumor suppression in the mouse immunogenic tumor model. The identification of the novel nonblocker anti-PD-1 Abs and their synergy with classical blocker Abs may be instrumental in potentiating immunotherapy strategies and antitumor activity.